Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct 1;2(4):e26102.
doi: 10.4161/jkst.26102. Epub 2013 Aug 19.

STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis

Christian Kosan  1 , Torsten Ginter  1 , Thorsten Heinzel  1 , Oliver H Krämer  2
Affiliations
Review

STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis

Christian Kosan et al. JAKSTAT. .

Abstract

The cytokine-inducible transcription factors signal transducer and activator of transcription 5A and 5B (STAT5A and STAT5B) are important for the proper development of multicellular eukaryotes. Disturbed signaling cascades evoking uncontrolled expression of STAT5 target genes are associated with cancer and immunological failure. Here, we summarize how STAT5 acetylation is integrated into posttranslational modification networks within cells. Moreover, we focus on how inhibitors of deacetylases and tyrosine kinases can correct leukemogenic signaling nodes involving STAT5. Such small molecules can be exploited in the fight against neoplastic diseases and immunological disorders.

Keywords: HAT; HDAC; HDACi; SIAH; STAT; STAT5; UBCH8; acetylation; cancer; leukemia.

PubMed Disclaimer

Figures

None
Figure 1. (A) STAT5 acetylation-sumoylation-phosphorylation switch. Binding of cytokines to receptors leads to the phosphorylation of STAT5 (P) at tyrosine and serine residues. For example, the interleukins IL-2 and IL-7 induce Janus tyrosine kinases phosphorylating STAT5 at tyrosine residues. The related HATs CBP and p300 catalyze acetylation of STAT5. Phosphorylated STAT5 dimers enter the nucleus and induce STAT5 gene expression promoting cell survival and proliferation. Acetylation (A) of STAT5 rivals sumoylation (S) and thereby allows STAT5 signaling. We postulate that the sumoylation of STAT5 occurs subsequent to a state in which STAT5 is phosphorylated and acetylated, in order to allow gene expression. HDAC9 has been shown to deacetylate STAT5; PTP, phosphatase catalyzing dephosphorylation of STAT5. UBCH9 and PIAS3 belong to the cellular sumoylation machinery (E2/E3 SUMO conjugase/ligase) and transfer SUMO2 to STAT5. SENP1 removes the sumoylation mark and subsequently allows a re-entry of STAT5 into signaling emanating from ligated receptors. The model is based on the works by Ma and colleagues, Van Nguyen and colleagues, and Beier and colleagues (see text for further details). (B) Tyrosine and lysine residues of STAT5 undergoing synergistic and antagonistic posttranslational modifications. The figure shows tyrosine and lysine moieties in STAT5A and STAT5B regulated by phosphorylation, acetylation, and sumoylation. Acetylation and sumoylation of one lysine moiety are mutually exclusive.
None
Figure 2. (A) Oncogenic STAT5 activation through FLT3-ITD. FLT3-ITD is a constitutively active, oncogenic driver mutant of FLT3. FLT3-ITD is frequently found in AML and ALL (acute myeloid/lymphoid leukemia). In contrast to FLT3, FLT3-ITD mainly locates to the endoplasmic reticulum (ER), from where it propels STAT5 signaling. Reactive oxygen species (ROS) are involved in the aberrant signaling of FLT3-ITD to STAT5. Resulting gene expression patterns linked to STAT5 promote uncontrolled cell proliferation and apoptosis resistance. It is unknown whether FLT3-ITD-dependent STAT5 activation is linked to the acetylation (A) or sumoylation (S) of STAT5. HSP90 stabilizes FLT3-ITD but is dispensable for the stability of FLT3. For (A) FLT3-ITD is provided as an example for an oncogenic kinase activating STAT5; similar findings were e.g., made for BCR-ABL. (B) HDACi antagonize STAT5 and FLT3-ITD. Histone deacetylase inhibitors (HDACi) eliminate FLT3-ITD and STAT5 via different, partially overlapping molecular mechanisms in AML cells. HDACi induce expression of the UBE2L6 gene encoding the E2 ubiquitin ligase UBCH8. In conjunction with SIAH1 and SIAH2 UBCH8 promotes the poly-ubiquitinylation and proteasomal degradation of FLT3-ITD. Acetylation events may play a role, e.g., HSP90 acetylation occurs in cells treated with HDACi that can block HDAC6. Acetylation of SIAH1, SIAH2, and UBCH8 has so far never been reported. Caspases are activated by HDACi in leukemic cells and these can cleave STAT5. The apoptotic cleavage of STAT5 impairs STAT5-dependent gene expression and this accelerates cellular demise.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wieczorek M, Ginter T, Brand P, Heinzel T, Krämer OH. Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev. 2012;23:293–305. doi: 10.1016/j.cytogfr.2012.06.005. - DOI - PubMed
    1. O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161–70. doi: 10.1056/NEJMra1202117. - DOI - PMC - PubMed
    1. Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors--an intimate relationship. Biochem Pharmacol. 2006;72:1538–46. doi: 10.1016/j.bcp.2006.04.013. - DOI - PubMed
    1. Krämer O, Moriggl R. Acetylation and sumoylation control STAT5 activation antagonistically. JAK-STAT. 2012;1:203–7. doi: 10.4161/jkst.21232. - DOI - PMC - PubMed
    1. Ferbeyre G, Moriggl R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta. 2011;1815:104–14. - PubMed